Boston Scientific

Methodology

Boston Scientific's interventional medical devices spanning cardiology, endoscopy, and neuromodulation provide growth above typical large-cap med-tech through innovation and market share gains. The company's focus on minimally invasive technologies positions it well for procedural growth trends. This fair value calculation works well for Boston Scientific given consistent new product launches and geographic expansion, though device recalls or clinical setbacks can create temporary volatility.

Methodology

Boston Scientific's PEG ratio typically ranges from 1.5-2.5, reflecting solid valuations for a medical device company with above-average growth from innovative products and international expansion. The company's track record of successful acquisitions and strong pipeline justify premium multiples to more mature device makers. Compare to peers like Medtronic and Abbott to assess whether Boston Scientific's growth trajectory and innovation pipeline warrant its positioning.

Methodology

Boston Scientific does not currently pay a dividend, reinvesting all capital into R&D, clinical trials, and strategic acquisitions to drive device innovation. The PEGY mirrors the PEG, offering no additional insight. For Boston Scientific investors, the focus remains on new product approvals, clinical trial results, and market share trends in key device categories rather than seeking traditional income returns.